RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background : Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients. However, IA is difficult to diagnose, especially in the aforementioned patient group. Recently, galactomannan assay (GMA) using enzyme immunoassay has been introduced in Korea. We evaluated its diagnostic usefulness in the diagnosis of IA and we analyzed the results according to the underlying diseases.
Materials and Methods : All patients who underwent GMA during the period from October 2007 to June 2008 were evaluated retrospectively. According to the criteria of European Organization for Research and Treatment of Cancer/Mycoses Study Group, IA was classified into four clinical categories: ‘proven’, ‘probable’, ‘possible’, and ‘non’ IA. Patients with ‘proven’ and ‘probable’ IA were used as the reference standards for IA. GMA was performed using Platelia Aspergillus EIA (Bio-Rad, Hercules, CA, USA). Optical density index ≥0.5 was considered positive.
Results : Of the 144 patients who underwent GMA, two patients were classificed as ‘proven’ IA and sixteen patients were ‘probable’ IA. Overall sensitivity, specificity, positive predictive value, and negative predictive value of the assay were 50% (95% confidence interval [CI95], 26-74%), 88% (CI95, 81-93%), 38% (CI95, 19-59%), and 93% (CI95, 86-97%), respectively. Among the 99 patients with underlying hematologic diseases, GMA showed 67% (CI95, 35-90%) sensitivity and 89% (CI95, 80- 94%) specificity, whereas in 45 patients with underlying diseases other than hematologic diseases, sensitivity and specificity of the assay were 17% (CI95, 0-64%) and 87% (CI95, 73-96%), respectively.
Conclusions : GMA showed high specificity, irrespective of the patient population. However, sensitivity of GMA was low and the assay was less sensitive in patients with underlying diseases other than hematologic diseases than in patients with hematologic diseases.

참고문헌 (Reference)

1 성흥섭, "침습성 아스페르길루스증 진단을 위한 Platelia Aspergillus 항원 검사법의 평가" 대한임상미생물학회 8 (8): 113-120, 2005

2 Aquino VR, "on the contribution of galactomannan for the diagnosis of invasive aspergillosis" 163 : 191-202, 2007

3 Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis" 347 : 408-415, 2002

4 Maertens J, "Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients" 186 : 1297-1306, 2002

5 Newcombe RG, "Two-sided confidence intervals for the single proportion: comparison of seven methods" 17 : 857-872, 1998

6 Verweij PE, "The Dutch Interuniversity Working Party for Invasive Mycoses" 36 : 1612-1616, 1998

7 Whiting P, "Sources of variation and bias in studies of diagnostic accuracy: a systematic review" 140 : 189-202, 2004

8 Verweij PE, "Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients" 33 : 1912-1914, 1995

9 De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group" 46 : 1813-1821, 2008

10 Wheat LJ, "Rapid diagnosis of invasive aspergillosis by antigen detection" 5 : 158-166, 2003